Across TCGA pan-cancer cohorts, TGM2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TGM2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TGM2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TGM2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.
CCRCC, LSCC, and PDAC are the cancer types where TGM2 tumor–normal differential expression is most reproducible.
mass-spec protein tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TGM2 mass-spec protein (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.